A Look At CVS Health (CVS) Valuation After Tennessee’s FAIR Rx Act Targets Its Integrated Model

The FAIR Rx Act passed by the Tennessee General Assembly has put CVS Health (CVS) at the center of a regulatory test, challenging its combined pharmacy benefit manager and retail pharmacy model in a key state.

See our latest analysis for CVS Health.

The FAIR Rx Act headlines are landing at a time when CVS Health’s 30 day share price return of 7.98% contrasts with a weaker 90 day share price return of 6.11% and a stronger 1 year total shareholder return of 23.68%. Recent regulatory headlines therefore appear against a backdrop of fading short term momentum but healthier long term outcomes for investors who have collected dividends along the way.

If you are looking beyond large integrated healthcare groups after this Tennessee development, it could be a good moment to see what else is moving in 33 healthcare AI stocks

With CVS Health trading at $77.94, an intrinsic value estimate implying a 72.19% discount, and a 23.91% gap to analyst targets, you have to ask: is this genuine mispricing, or is future growth already fully reflected?

Most Popular Narrative: 25.1% Undervalued

According to the most followed narrative, CVS Health’s fair value of $104.01 sits well above the last close at $77.94, putting a spotlight on the size of that gap and how it might be closed.

Regardless of these risks in the near term, the present valuation for CVS indicates that the stock is undervalued by the street. At a P/E ratio of 10x, or significantly lower than the sector average, CVS prices in at a 71% discount to its peers and points to some significant upside should it be able to execute on its turnaround strategy. In H1 2024, revenue in the HCB segment increased by 23% YoY, indicating promising growth avenues. That undervaluation of CVS, in addition to expected EPS growth in 2025, just makes it a stock to closely watch as it works itself out of costs versus profitability for the long-term investor.

Read the complete narrative.

Want to see what really underpins that $104.01 fair value? The narrative leans on accelerating earnings, a reset profit base, and a long runway for healthcare revenues. Curious which assumptions matter most and how they fit together? The full story spells out the earnings path, margin profile, and cash flow expectations that sit behind that valuation.

Result: Fair Value of $104.01 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on CVS containing medical cost pressures and regulatory risk around its integrated model. Both of these factors could quickly challenge that undervaluation story.

Find out about the key risks to this CVS Health narrative.

Another View: Earnings Multiple Sends a Different Signal

Here is where the picture gets more complicated. On current numbers, CVS Health trades on a P/E of 56.5x, compared with 24.3x for the wider US Healthcare industry and 18x for its peer group. Our fair ratio for CVS sits lower at 39.5x, which suggests the market may already be baking in a lot of optimism.

For you as an investor, that gap means the story is not just about a big discount to fair value models. It is also about paying a richer price for each dollar of earnings than many peers. Is this a case where earnings need to catch up to support the equity story, or is the market overcompensating for recent volatility?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment, this is a moment to look at the data yourself and decide what really stands out. To weigh both the concerns and the potential upside, start by checking the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you are weighing what to do next after reading about CVS Health, do not stop here. Fresh ideas can often come from looking one step beyond your original watchlist.

• Spot potential bargains early by scanning screener containing 24 high quality undiscovered gems that combine solid fundamentals with the potential to surprise the market.
• Strengthen the quality of your portfolio by focusing on companies featured in the solid balance sheet and fundamentals stocks screener (42 results) that put financial resilience front and center.
• Build a steadier income stream by reviewing the 13 dividend fortresses that highlight companies offering higher yields with an eye on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com